Pre-diabetes in overweight youth and early atherogenic risk by Burns, Stephen F. et al.
Pre-diabetes in overweight youth and early atherogenic risk
Stephen F. Burns, Ph.D.1,3, SoJung Lee, Ph.D.1, Fida Bacha, M.D.4, Hala Tfayli, M.D.5, 
Tamara S. Hannon, M.D.6, and Silva A. Arslanian, M.D.1,2
1Division of Weight Management and Wellness, Children's Hospital of Pittsburgh of UPMC 
Pittsburgh, Pennsylvania 15201
2Division of Pediatric Endocrinology, Metabolism and Diabetes Mellitus Children's Hospital of 
Pittsburgh of UPMC Pittsburgh, Pennsylvania 15201
3Physical Education and Sports Science Academic Group Nanyang Technological University, 
Singapore 637616
4Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX
5Department of Pediatrics and Adolescent Medicine, American University of Beirut, Beirut, 
Lebanon
6Departments of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
Abstract
Purpose—To compare atherogenic lipoprotein particles and vascular smooth muscle biomarkers 
in overweight youth with pre-diabetes (PD) vs. normal glucose tolerance (NGT).
Methods—144 adolescents (60 black, 84 white; 102 female; PD=45, NGT=99) aged 10-19 years 
underwent a fasting blood draw and 2-hr OGTT. Lipoprotein particle size and subclass 
concentration and vascular smooth muscle biomarkers (ICAM-1, VCAM-1 and E-selectin) were 
compared between youth with PD and NGT.
Results—Compared with NGT, PD adolescents had smaller LDL (mean ± SE: 20.5 ± 0.1 vs. 
21.0 ± 0.1 nm; P=0.002) and HDL (8.62 ± 0.05 vs. 8.85 ± 0.04 nm; P=0.013) size and elevated 
medium small (159.2 ± 10.3 vs. 123.8 ± 6.4 nmol/L; P=0.037) and very small (626.3 ± 45.4 vs. 
458.5 ± 26.4 nmol/L; P=0.032) LDL particle concentrations, after adjustment for race and BMI. 
Further adjusting for fasting insulin or visceral adiposity obviated these differences between the 
groups except for LDL size. ICAM-1 and E-selectin did not differ in youth with PD but correlated 
with LDL and HDL size, and small LDL particle concentrations.
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Conclusions—Overweight adolescents with PD have an atherogenic lipoprotein profile of small 
LDL and HDL size and increased concentrations of small LDL, moderated by insulin resistance 
and visceral adiposity, but independently driven by dysglycemia for LDL size. Associations 
between smooth muscle biomarkers and lipoproteins could be an early signal heralding the 
atherogenic process. It remains to be determined if correction of dysglycemia and associated 
lipoprotein abnormalities in obese youth could prove effective in halting this process.
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1. INTRODUCTION
The transition from normal glucose tolerance (NGT) to overt type 2 diabetes mellitus is 
characterized by an intermediate state termed pre-diabetes (PD) which is representative of 
individuals with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) [1,2]. 
Data from the National Health and Nutrition Examination Survey (NHANES) in 2005–2006 
found that the overall prevalence of PD in youth in the U.S. was 16.1% but that the 
prevalence was 1.6- and 2.6-fold higher in overweight and obese youth, respectively, 
compared with normal-weight children [3].
Overweight youth with PD often present with dyslipidemia including higher total cholesterol 
and low-density lipoprotein (LDL) cholesterol, higher triglycerides (TG) and lower high-
density lipoprotein (HDL) cholesterol [3,4,5]. However, traditional lipid measures only 
partially predict future cardiovascular disease risk [6,7,8] and adult studies have found 
adverse lipoprotein particle size and subclass concentration in individuals with PD [9,10]. In 
youth, only one study [11] has examined the relationship between overweight, glycemia and 
atherogenic lipoprotein particles in 21 obese adolescents with PD (IFG and IGT) compared 
with 74 normoglycemic, obese counterparts. Despite similar standard lipid profiles, those 
youth with PD had smaller LDL and HDL particle size, higher concentrations of small LDL 
and HDL particles and lower concentrations of large HDL particles, the significance of all of 
which disappeared except for LDL particle size, after controlling for Homeostasis Model 
Assessment- Insulin Resistance Index (HOMA-IR) [11]. However, the authors highlighted 
that their study contained a relatively small number of youth with PD, which they suggest 
could lead to a type II error, and was largely represented by African Americans who made 
up ~90% of the PD group and ~78% of the normoglycemic youth [11]. Moreover, they were 
unable to examine the role of visceral adiposity in mediating the relationship between 
glycemia and atherogenic lipoprotein particles which has been highlighted in prior studies of 
youth [12,13]. Finally, circulating biomarkers of vascular smooth muscle function are 
increased in the early stage of vascular fatty lesions and play an important role in the 
formation of the atherosclerotic plaque [14] alongside lipoproteins. However, there has been 
no examination of these vascular biomarkers in relation to glycemia and PD in youth.
Thus, the aim of the present study was: 1) to compare differences in lipoprotein particle size 
and concentration in a large multi-racial (black/white) cohort of overweight adolescents with 
PD vs. NGT; 2) to examine the role of whole body and visceral adiposity in mediating 
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differences in lipoprotein particle size and concentration between these two groups; and 3) 
to investigate differences in biomarkers of vascular smooth muscle function in overweight 
youth with PD vs. NGT.
2. METHODS
2.1 Subjects
Participants were 144 black and white overweight/obese (body mass index, BMI≥85th 
percentile) adolescents aged 10-19 years. For some participants data on lipids or lipoprotein 
particle size and subclass concentration were reported before but within a different context 
and specific aims, as part of a grant investigating childhood insulin resistance 
[12,15,16,17,18]. None of these previous studies examined the role of established clinical 
definitions of glycemia or PD in youth on lipoprotein particle size or subclass concentration 
or vascular smooth muscle markers. Study participants were recruited through newspaper 
and bulletin board advertisements. All studies were approved by the Institutional Review 
Board of the University of Pittsburgh. All participants and their parents gave written 
informed assent and consent after a thorough explanation of the proposed study. Exclusion 
criteria included diagnosed diabetes and the use of medications that influence glucose and 
lipid metabolism or blood pressure. These medications included oral contraceptive pills, 
metformin, anti-psychotic drugs, fish oils and drugs for dyslipidemia and hypertension. 
Participants' health was assessed by medical history, physical examination and routine 
hematological and biochemical tests. Pubertal development was assessed by physical 
examination according to Tanner criteria.
2.2 Anthropometry
All participants were admitted to the Children's Hospital of Pittsburgh National Institutes of 
Health funded Pediatric Clinical and Translational Research Center. Body height and weight 
were measured to the nearest 0.1cm and 0.1 kg, respectively, using standardized equipment.
2.3 Body composition
Total body fat was assessed using dual energy X-ray absorptiometry (DEXA). Abdominal 
subcutaneous and visceral adipose tissues (VAT) were determined from a single axial image 
(10-mm thickness) of the abdomen at the level of the L4-L5 intervertebral disc using 
computed tomography. Both methods have been described previously [19].
2.4 Fasting blood draw and Oral glucose tolerance test (OGTT)
After an overnight fast, blood samples were obtained for lipoprotein particle size and 
concentration and vascular smooth muscle biomarkers, followed with a 2-h OGTT (1.75 
g/Kg glucola, maximum 75 g) in all participants. Blood samples were obtained at −15, 0, 15, 
30, 60, 90 and 120 minutes for determination of glucose and insulin concentrations.
2.5 Biochemical measurements
Plasma glucose was measured using a glucose analyzer (YSI, Yellow Springs, OH) and 
insulin concentrations were measured by radioimmunoassay [15]. Plasma lipid 
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concentrations (total, HDL and LDL cholesterol and total and very low density lipoprotein 
(VLDL)-TG) were determined using the standards of the Centers for Disease Control and 
Prevention as described previously [12]. For total and HDL cholesterol and total TG intra-
assay coefficients of variation (CV) were 1.0%, 1.8% and 1.8% and inter-assay CV 1.6%, 
2.6% and 3.7%, respectively. LDL and VLDL were calculated using the Friedewald 
equation [20]. Concentrations of lipoprotein subclasses and particle size were determined 
using nuclear magnetic resonance (NMR) spectroscopy at LipoScience Inc. using the 
LipoProfile-2 algorithm (LipoScience Inc., Raleigh, NC) [21]. Using this method the 
quantity of each subclass is reported in particle concentration units (nanomoles of particles 
per liter for VLDL and LDL and micromoles per liter for HDL). The VLDL, LDL, and HDL 
were separated into 10 subclass categories: large VLDL (including chylomicrons) (>60 nm), 
medium VLDL (35–60 nm), small VLDL (27–35 nm), intermediate-density lipoprotein 
(IDL) (23–27 nm), large LDL (21.2–23 nm), medium-small LDL (19.8 –21.2 nm), very 
small LDL (18 –19.8 nm), large HDL (8.8 –13 nm), medium HDL (8.2– 8.8nm), and small 
HDL (7.3– 8.2 nm). Average lipoprotein particle sizes were computed as the sum of the 
diameter of each subclass multiplied by its relative mass percentage as estimated from the 
amplitude of its methyl NMR signal [12,21]. Intra-assay and inter-assay coefficients of 
variation were estimated from two pools of plasma, one with high TG and low HDL and the 
other with low TG and high HDL [22]. Both intra- and inter-assay CV were ≤4% for total 
VLDL, HDL and LDL particles and typically ≤6% for all subclass concentrations [22]. 
Intra- and inter-assay CV for HDL and LDL particle size were <1% and for VLDL size <3% 
[22]. Biomarkers of vascular smooth muscle function, intercellular adhesion molecule-1 
(ICAM-1), vascular adhesion molecule-1 (VCAM-1) and E-selectin, were quantified using 
commercially available double-sandwich enzyme-linked immunoassays (R&D Systems, 
Minneapolis, MN). Intra-assay CV for ICAM-1, VCAM-1 and E-selectin were 5.96%, 
4.91% and 6.78% and inter-assay CV 9.37%, 9.01% and 8.98%, respectively.
2.6 Statistical analysis
Statistical procedures were performed using SPSS 21.0 for Windows (SPSS, Chicago, IL). 
To investigate the relationship of the category of glycemia with lipoprotein particle size and 
concentration and markers of vascular smooth muscle function, participants were divided 
into two groups: i) NGT and ii) PD. Individuals with NGT had both normal fasting and 2-hr 
glucose concentrations. Individuals with PD were those with either IFG or IGT which was 
defined as fasting plasma glucose between 5.6 and 6.9 mmol/L or plasma glucose between 
7.8 and 11.0 mmol/L at 120 min of the OGTT, respectively [1]. Differences in categorical 
variables (sex, race and Tanner stage) were determined by Chi-square analysis. Normality 
was checked for all continuous variables using a Kolmogorov-Smirnoff test and differences 
in variables between groups determined using independent t-test or Mann Whitney test. 
Adjustments for race and different measures of adiposity (BMI, fat mass, percentage body 
fat and VAT) were made using ANCOVA with data for non-normally distributed variables 
log transformed beforehand. Further ANCOVA was used to adjust for race and BMI with 
fasting insulin. Stepwise multiple regression, in all participants combined, was used to 
assess the effect of category of glycemia (NGT vs PD) along with race, sex, age, Tanner 
stage (II–III or IV–V), adiposity (BMI or VAT) and fasting insulin on lipoprotein particle 
size and concentration. Relationships of vascular smooth muscle markers with lipoprotein 
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size and subclass concentration were determined using Spearman rank correlations (rs) as 
data for vascular markers were not normally distributed. Data are presented as mean ± 
standard error (SE). Significance was set at P<0.05.
3. RESULTS
3.1 Physical and metabolic characteristics
Physical and metabolic characteristics of the participants by glycemic category are presented 
in Table 1. The groups were similar in age and development. All youth were Tanner stage II 
or greater. Distribution of the sexes was similar in both groups but with more females than 
males overall. There was a significant racial difference between NGT and PD, such that the 
group with PD had significantly more white than black youth. Adolescents with PD had 
significantly greater VAT, higher fasting and 2-h OGTT glucose concentrations, and higher 
fasting insulin compared with NGT but with no difference in HbA1c concentrations. When 
Log VAT was adjusted for race the difference between the two groups remained significant 
(P=0.022). In the PD group, 9 youth had isolated IFG, 31 had isolated IGT and 5 had both 
IFG and IGT.
3.2 Lipid concentrations
Fasting lipid profiles determined by chemical analysis are presented in Table 1. There was 
no difference in cholesterol or LDL-cholesterol between groups but youth with PD had 
significantly lower concentrations of HDL-cholesterol and higher concentrations of TG and 
VLDL-TG than youth with NGT. Differences in HDL remained after correcting for race and 
any measure of adiposity (BMI, P=<0.001; fat mass, P=0.001; Log percentage body fat, 
P=0.001; Log VAT, P<0.001). Including Log fasting insulin (P=0.001) in the adjustment for 
race and BMI did not change the significant difference in HDL between PD and NGT 
groups. Differences in VLDL remained significant between the two groups when correcting 
for race and BMI (P=0.031) but not race and Log VAT (P=0.086); or race, BMI and Log 
insulin (P=0.11). There were no differences in TG between PD and NGT after correcting for 
race, adiposity and Log insulin.
3.3 Lipoprotein particle size
Figure 1 depicts LDL (Figure 1A) and HDL (Figure 1B) particle size in youth with NGT vs. 
PD. Both LDL and HDL particle size were significantly smaller in adolescents with PD. 
These differences remained significant in the LDL particle after adjusting for race and any 
measure of adiposity (BMI, fat mass, Log percentage body fat and Log VAT), but 
disappeared for HDL particle size after adjusting for Log VAT (P=0.096). Adjusting for 
race, BMI and Log fasting insulin did not change the significant difference between groups 
in the LDL particle but removed differences in the HDL particle between youth with PD and 
NGT. There was no difference in VLDL particle size between groups (NGT, 53.7 ± 1.0 nm 
vs. PD, 55.5 ± 1.5 nm; P=0.282).
3.4 Lipoprotein particle concentrations
Figure 2 shows lipoprotein particle concentrations. Large LDL (Figure 2A) particle 
concentrations were lower whilst, conversely, medium small (Figure 2B) and very small 
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(Figure 2C) LDL particle concentrations were higher in the youth with PD than those with 
NGT. These differences in the concentration of LDL particles remained after correcting for 
race and most measures of adiposity (BMI, fat mass or percentage body fat), but not race 
and Log VAT (large LDL, P=0.057; medium small LDL, P=0.130; very small LDL, 
P=0.111). Differences in LDL particles between groups also disappeared after correcting for 
race, BMI and Log insulin. Large HDL concentrations (Figure 2D) were lower in 
adolescents with PD than those with NGT but this difference disappeared after correcting for 
race and adiposity. There were no differences in medium (Figure 2E) or small (Figure 2F) 
HDL particle concentrations between groups. Large (PD, 4.2 ± 0.6 nmol/L vs. NGT, 2.4 ± 
0.3 nmol/L; P=0.002) and medium (PD, 21.5 ± 2.1 nmol/L vs. NGT, 15.6 ± 1.2 nmol/L; 
P=0.006) VLDL particle concentrations were higher in youth with PD than those with NGT, 
with no difference in small VLDL (PD, 30.9 ± 2.0 nmol/L vs. NGT, 28.2 ± 1.5 nmol/L; 
P=0.302). Adjusting for Log fasting insulin along with race and BMI obviated differences in 
all VLDL particles between groups.
As IFG and IGT have distinct pathophysiologic etiologies we further compared the data 
among 9 youth with isolated IFG and 31 with isolated IGT. Against the backdrop of the few 
IFG subjects, there were no significant differences in lipoprotein size or subclass 
concentration between the two groups (data not shown). The significant differences between 
PD and NGT in LDL and HDL size, medium and small LDL, and large and small VLDL 
concentrations persisted when only youth with isolated IGT were compared with NGT 
adolescents (data not shown).
Evaluation based on HbA1C diagnostic categories (1) of PD (5.7 to < 6.5%) (n=33) vs. 
normal (<5.7%) (n=111) revealed significantly lower large (PD, 2.2 ± 0.6 nmol/L vs. 
Normal, 3.2 ± 0.3 nmol/L; P=0.012) and medium (PD, 13.2 ± 2.1 nmol/L vs. Normal, 18.7 
±1.2 nmol/L; P=0.014) VLDL particle concentrations in PD youth, but these differences 
disappeared after correcting for race and BMI. No other differences in lipoprotein particle 
size and concentration existed. Only 9 youth had an HbA1C ≥6.0% preventing any further 
comparison between groups using an International Definition of PD (HbA1C 6.0–6.4%) as 
has been done by others [23].
3.5 Contribution of glycemia to lipoprotein particle size and concentration
Category of glycemia together with Log fasting insulin, race and sex explained 24.3% of the 
variance in LDL particle size (Table 2) but did not predict HDL or VLDL size (data not 
shown). When BMI was replaced with VAT in the model, category of glycemia (partial r= 
−0.237, P=0.008) predicted 24.6% of LDL particle size along with Log VAT, Log fasting 
insulin and Tanner stage. Category of glycemia was the sole predictor for 3.1% of large 
LDL particle concentrations (partial r= −0.175, P=0.037) and significantly predicted 18.4% 
of medium small and 18.3% of very small LDL particle concentration in combination with 
Log insulin and sex (Table 2). Substitution of BMI with VAT removed category of glycemia 
as a predictor of all LDL subclass. Category of glycemia did not predict HDL or VLDL 
particle concentrations.
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3.6 Vascular smooth muscle biomarkers
Concentrations of the vascular smooth muscle biomarkers, ICAM-1, VCAM-1, and E-
selectin were not different between NGT and PD (Table 1). The ICAM-1 concentration 
correlated significantly with the LDL, HDL and VLDL particle size (rs= −0.222, rs= −0.213, 
rs= 0.178 respectively, P=<0.05), with concentrations of large, medium small and very small 
LDL (rs= −0.183, rs= 0.173, rs= 0.217, respectively, P<0.05), and with large HDL particles 
and large VLDL and chylomicron particles (rs= −0.247, rs= 0.236, respectively, P<0.01). 
Similarly, E-selectin correlated with LDL and HDL particle size (rs= −0.199, rs= −0.189 
respectively, P<0.05), with medium small and very small LDL particle concentrations (rs= 
0.176, rs= 0.190 respectively, P<0.05), and large HDL particle concentration (rs= −0.196, 
P=0.020). VCAM-1 did not correlate with lipoprotein size or concentration.
4. DISCUSSION
The present study demonstrates that overweight youth with PD have an atherogenic 
lipoprotein profile of small dense LDL and HDL particle size, and high concentrations of 
small LDL and large VLDL particles, and low concentrations of large HDL particles, 
compared with their NGT peers. Differences in the LDL particle size remained even after 
adjustment for various adiposity indices and a surrogate of insulin sensitivity suggesting an 
independent effect of hyperglycemia on LDL particle size. Our data confirm findings from a 
smaller previous study which showed that obese youth with PD (n=21), primarily black, 
have a significantly more atherogenic lipoprotein profile compared with their 
normoglycemic peers [11]. The present investigation extends and strengthens the previous 
findings by examining a much larger multi-racial cohort of youth with PD, and reveals a role 
of visceral adiposity in the observed lipoprotein differences between youth with PD and 
NGT except for LDL particle size where dysglycemia itself plays a role. Lastly, the 
pathological translation of this atherogenic profile in youth with PD was examined by 
measuring circulating biomarkers of vascular smooth muscle dysfunction, with significant 
relationships noted between these markers and LDL and HDL particle size.
In youth, data from the NHANES in 2005–2006 found that the overall prevalence of PD was 
16.1% [3]. However, the prevalence in overweight (BMI 85th–<95th percentile, 18.3%) and 
obese (BMI ≥95th percentile, 30.0%) adolescents was considerably greater than that of their 
normal weight counterparts (11.6%) [3]. Importantly, PD in youth was also associated with 
an increased number of cardiometabolic risk factors including low HDL-cholesterol and 
high triglycerides [3]. Our data confirm that youth with PD exhibit a worse standard lipid 
profile than their normoglycemic counterparts and also have an atherogenic lipoprotein 
profile exemplified above. Even though the risk for development of cardiovascular disease 
in youth with PD is not known [5], the current findings are disturbing given that large 
prospective studies in adults with PD show an increased risk of all cause and cardiovascular 
mortality [24,25] and non-fatal cardiovascular events [26,27,28]. The increased risk is 
probably related to the poor lipoprotein subclass profile [9,10] which has been shown to be 
associated with carotid intima media thickness in adults [29], and a strong predictor of 
cardiovascular disease [7,8]. Moreover, childhood LDL and HDL have been related to 
carotid intima media thickness and its progression in adulthood [30], with normal weight 
Burns et al. Page 7
Metabolism. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and obese youth with favorable lipoprotein concentrations having lower intima media 
thickness in adulthood than obese youth with unfavorable profiles [32]. Additionally, since 
early atherosclerotic plaque formation and changes in carotid intima media thickness begin 
in childhood and have been related to hyperglycemia [32,33], consideration should be given 
to early treatment of hyperglycemia and associated lipoprotein abnormalities in overweight 
youth with PD.
We previously demonstrated that, in normal weight and overweight otherwise healthy youth, 
in vivo clamp-measured insulin sensitivity [18] and waist circumference [12] are important 
determinants of an atherogenic lipoprotein profile. Similar observations were made by 
others using a variety of methodologies [3,13,34,35,36,]. Magge and colleagues [11] 
reported that controlling for HOMA-IR eliminated the differences in lipoproteins between 
pre-diabetic and normoglycemic obese youth except for small LDL particle size, but 
controlling for age, sex, race, Tanner stage and BMI did not abolish the lipoprotein 
differences between the two groups [11]. In the current study, the persistence of a difference 
in LDL particle size between PD and NGT youth, after correcting for visceral adiposity and 
fasting insulin or HOMA-IR (data not shown), together with the data of Magge and 
colleagues [11], strongly suggest an independent contribution of hyperglycemia per se to 
LDL particle size. Indirect support for this is the recent observation from the TODAY trial 
that glycosylated hemoglobin was directly related to LDL concentrations independent of 
BMI in youth with type 2 diabetes [37].
Circulating biomarkers of vascular smooth muscle function are increased in response to 
inflammation in the early stage of fatty lesions and play a role in the initial formation of the 
atherosclerotic plaque [14] beginning in childhood [28,38]. In the current study, there were 
no differences in the concentrations of ICAM-1, VCAM-1 and E-selectin between youth 
with and without PD. The ability of these indirect markers to differentiate early endothelial 
dysfunction in overweight youth with or without PD could be questioned, and more direct 
endothelial challenge tests may be needed to distinguish endothelial dysfunction in youth 
with PD. Alternatively, cytokine markers of arterial inflammation, such as interleukin-6 and 
components of its transsignalling system which have been shown to correlate with cellular 
adhesion molecules and arterial stiffness in adults with metabolic syndrome [39], may be 
better to characterize early endothelial function in youth. Nevertheless, in the present study 
ICAM-1 and E-selectin were associated with the size of both LDL and HDL particles, and 
LDL particle concentration suggesting a possible link between atherogenic lipoprotein 
particles and the initial stages of smooth muscle dysfunction and atherosclerosis. Whether 
such differences would evolve over time with persistence of dysglycemia, obesity and 
dyslipidemia remain to be investigated.
The classification of PD includes individuals with IFG or IGT, with significant debate over 
the years, the most recent just released in 2014, about the various definitions [40]. For the 
purpose of the present study, adolescents with PD were clustered together and represented 
obese youth with IFG, IGT or both. Since IFG and IGT are reported to have distinct 
pathophysiologic etiologies [2,41,42], we further sub-analyzed and compared youth with 
isolated IFG versus isolated IGT, but found no significant differences in the lipoprotein 
profiles between the two. The paucity of numbers however is a limitation preventing any 
Burns et al. Page 8
Metabolism. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
conclusion and larger multi-center studies are needed to examine this issue further. 
Additionally, both IFG and IGT can be transient states with poor reproducibility of the oral 
glucose tolerance test in youth and adults [40,43], and progression from IGT to diabetes is 
far from guaranteed in adults and youth [44,45]. Thus, longitudinal examination of changes 
in atherogenic lipoproteins in relation to persistent hyperglycemia in obese youth is needed.
There are a number of limitations to the present study. This is a cross-sectional evaluation of 
data amassed with no a priori power analysis. Thus, our numbers may be insufficient to 
preclude the possibility of a type II error when comparing NGT and PD youth. However, our 
study contains more than twice the number of youth with PD than the study by Magge and 
colleagues [11] and is confirmatory of their work. Collectively, these studies provide 
evidence on the important relationship of PD with lipoproteins in youth. Another potential 
limitation is that visceral adiposity, an important modulator of lipoprotein particle size [12], 
was larger in youth with PD vs. NGT. However, the significant difference in LDL particle 
size between PD and NGT persisted even after adjusting for visceral fat. Finally, the use of 
fasting insulin, or its inverse or HOMA, as surrogate estimates of insulin sensitivity, may 
perhaps be viewed as a limitation. However, our group has shown that these surrogate 
estimates correlate strongly with in vivo insulin sensitivity measured with the 
hyperinsulinemic-euglycemic clamp in youth with NGT, PD and diabetes [46], particularly 
when applied to large numbers.
5. CONCLUSIONS
In summary, the present study shows that overweight/obese youth with pre-diabetes exhibit 
an atherogenic lipoprotein profile of small dense LDL and small HDL in combination with 
increased concentrations of small LDL and large VLDL particles, and low concentrations of 
large HDL particles compared with their normoglycemic counterparts. Our data suggest that 
physicians screening or treating overweight youth with PD should look beyond traditional 
lipid measurements, particularly for LDL cholesterol, to enable a better assessment of early 
cardiovascular risk. While significant relationships exist between atherogenic particles and 
vascular smooth muscle biomarkers, the absence of differences in these biomarkers between 
pre-diabetes and NGT provides hope that correction of dysglycemia, obesity and the 
lipoprotein abnormalities at this early stage might prevent the genesis of atherosclerosis.
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LIST OF ABBREVIATIONS
BMI body mass index
CV coefficients of variation
DEXA dual energy X-ray absorptiometry
HDL high-density lipoprotein
HOMA-IR Homeostasis Model Assessment- Insulin Resistance Index
ICAM-1 intercellular adhesion molecule-1
IFG impaired fasting glucose
IGT impaired glucose tolerance
LDL low-density lipoprotein
NGT normal glucose tolerance
NHANES National Health and Nutrition Examination Survey
NMR nuclear magnetic resonance
OGTT oral glucose tolerance test
PD pre-diabetes
TG triglycerides
VAT visceral adipose tissues
VCAM-1 vascular adhesion molecule-1
VLDL very low-density lipoprotein
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Figure 1. 
LDL (panel A) and HDL (panel B) particle size in overweight/obese youth with normal 
glucose tolerance (NGT) and pre-diabetes (PD). Differences compared using an independent 
t-test or Mann Whitney test. Adjusteda P is for the difference after adjusting for race and 
BMI using ANCOVA. Adjustedb P is for the difference after adjusting for race, BMI and 
Log fasting insulin using ANCOVA.
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Figure 2. 
Concentrations of large (panel A), medium-small (panel B) and very small (panel C) LDL 
particles, and large (panel D), medium (panel E) and small (panel F) HDL particles in youth 
with NGT and PD. Differences compared using an independent t-test or Mann Whitney test. 
Adjusteda P is for the difference after adjusting for race and BMI using ANCOVA. 
Adjustedb P is for the difference after adjusting for race, BMI and Log fasting insulin using 
ANCOVA.
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Table 1
Physical and metabolic characteristics, lipid profile and vascular smooth muscle markers of participants by 
category of glycemia (normal glucose tolerance, NGT and pre-diabetes, PD).
NGT (n=99) PD (n=45) P
Physical characteristics
 Age (years)b 14.4 ± 0.2 14.7 ± 0.3 0.474
 Sex (M/F)a 30/69 12/33 0.656
 Race (B/W)a 50/49 10/35 0.001
 Tanner stagea 0.427
   II–III 21 7
   IV–V 78 38
 BMI (kg/m2)b 34.9 ± 0.8 36.1 ± 1.0 0.352
 BMI percentilec 97.1 ± 0.3 98.3 ± 0.2 0.111
 Body fat (%)c 42.7 ± 0.8 44.6 ± 0.7 0.471
 Fat mass (kg)b 39.1 ± 1.4 42.8 ± 1.8 0.132
 VAT (cm2)c 63.7 ± 4.4 81.1 ± 5.7 0.001
Metabolic characteristics
 Fasting glucose (mmol/L)b 4.87 ± 0.04 5.25 ± 0.07 <0.001
 2-h glucose (OGTT) (mmol/L)c 6.41 ± 0.08 8.51 ± 0.19 <0.001
 HbA1c (%) 5.3 ± 0.0 5.3 ± 0.1 0.430
 (mmol/mol)c (34.0 ± 1.4) (34.0 ± 2.0)
 Fasting insulin (pmol/L)c 196.8 ± 16.8 234.0 ± 23.4 0.027
Fasting lipid profile
 Total cholesterol (mmol/L)b 4.16 ± 0.10 4.24 ± 0.12 0.640
 HDL-cholesterol (mmol/L)c 1.38 ± 0.07 1.04 ± 0.05 0.001
 LDL-cholesterol (mmol/L)b 2.24 ± 0.10 2.48 ± 0.12 0.138
 TG (mmol/L)c 1.22 ± 0.06 1.55 ± 0.12 0.013
 VLDL-TG (mmol/L)c 0.23 ± 0.01 0.31 ± 0.02 0.004
Vascular smooth muscle markers
 ICAM-1 (ng/mL)c 222.5 ± 9.9 231.9 ± 17.0 0.852
 VCAM-1 (ng/mL)c 683.6 ± 26.1 722.8 ± 43.9 0.498
 E-selectin (ng/mL)c 53.6 ± 3.6 48.7 ± 4.0 0.595
Values are mean ± SE.
a
Race, gender and Tanner stages compared using Chi-square.
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bCompared using independent t-test
cCompared using Mann Whitney test
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Table 2
Stepwise multiple linear regression to quantify the independent contribution of category of glycemia [(normal 
glucose tolerance (NGT) and pre-diabetes (PD)], race, sex, age, Tanner stage, BMI and fasting insulin to LDL 
particle size and concentration.
Dependent variable Independent variablesa Partial r P R
2
LDL Size Glucose category −0.218 0.010
Race −0.173 0.042
Sex 0.205 0.016
Age 0.054 0.529
Tanner stage 0.104 0.223
BMI −0.031 0.715
Log fasting insulin −0.344 <0.001 0.243
Medium small LDL concentration Glucose category 0.170 0.045
Race 0.082 0.335
Sex −0.184 0.029
Age −0.023 0.787
Tanner stage −0.075 0.383
BMI 0.033 0.700
Log fasting insulin 0.356 <0.001 0.184
Very small LDL concentration Glucose category 0.182 0.031
Race 0.101 0.235
Sex −0.171 0.043
Age −0.056 0.512
Tanner stage −0.068 0.425
BMI 0.058 0.500
Log fasting insulin 0.352 <0.001 0.183
a
Final model
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